David Kan
Impact in
-
- Monoclonal and Polyclonal Antibodies Research
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments
Papers in ⓘ
- Genetics 5
- Chronic Lymphocytic Leukemia Research 5
-
- Chronic Myeloid Leukemia Treatments 5
- Co-authors
- Stephen Castaneda (9 shared papers)Amy Camuso (11 shared papers)Christine Flefleh (11 shared papers)Kelly McGlinchey (10 shared papers)Ivan Inigo (11 shared papers)Shang‐Fan Yu (2 shared papers)Jenny Boström (1 shared paper)Wenyan Man (1 shared paper)
- Journals
- Blood (4 papers)Clinical Cancer Research (3 papers)Journal of Clinical Oncology (3 papers)Cancer Research (2 papers)Journal of Psychoactive Drugs (1 paper)
- Partner nations
- United StatesGermanyNetherlands
In The Last Decade
David Kan
21 papers receiving 775 citations
Peers
Comparison fields: 5 of 73
- Radiology, Nuclear Medicine and Imaging 310
- Hematology 148
- Oncology 322
- Genetics 117
- Rheumatology 83
Countries citing papers authored by David Kan
This map shows the geographic impact of David Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kan more than expected).
Fields of papers citing papers by David Kan
This network shows the impact of papers produced by David Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kan. The network helps show where David Kan may publish in the future.
Co-authors
The 25 scholars most cited alongside David Kan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 263 | |
| 2 | 2006 | 113 | |
| 3 | 2015 | 69 | |
| 4 | 2005 | 66 | |
| 5 | 2006 | 60 | |
| 6 | BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo | 2005 | 38 |
| 7 | 2008 | 37 | |
| 8 | 2006 | 28 | |
| 9 | 2005 | 26 | |
| 10 | 2016 | 25 | |
| 11 | 2005 | 22 | |
| 12 | 2022 | 17 | |
| 13 | 2005 | 14 | |
| 14 | 2004 | 9 | |
| 15 | 2015 | 5 | |
| 16 | 2005 | 5 | |
| 17 | Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668 | 2004 | 3 |
| 18 | The impact of the cultural revolution on Chinese higher education | 1971 | 2 |
| 19 | 2017 | 1 | |
| 20 | 2004 | 1 |
About David Kan
David Kan is a scholar working on Genetics, Hematology, Oncology, Cancer Research and Immunology and Allergy, having authored 22 papers that have together received 805 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers), Click Chemistry and Applications (3 papers), Opioid Use Disorder Treatment (2 papers) and Microtubule and mitosis dynamics (2 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (310 citations), Hematology (148 citations), Oncology (322 citations), Genetics (117 citations) and Rheumatology (83 citations). David Kan has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Stephen Castaneda, Amy Camuso, Christine Flefleh, Kelly McGlinchey, Ivan Inigo, Shang‐Fan Yu, Jenny Boström, Wenyan Man, Franklin Peale and Christian Wiesmann. Their work appears in journals such as Blood, Clinical Cancer Research, Journal of Clinical Oncology, Cancer Research and Journal of Psychoactive Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.